UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 796

Sortiert nach

Differences between male and female systemic lupus erythematosus in a multiethnic population

Journal of rheumatology, 2012-04, Vol.39 (4), p.759

2012

Volltextzugriff (PDF)

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

The Lancet (British edition), 2011, Vol.377 (9767), p.721-731

2011

Volltextzugriff (PDF)

Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response

Annals of the rheumatic diseases, 2012-08, Vol.71 (8), p.1343-1349

2012

Volltextzugriff (PDF)

Associates and predictors of pleurisy or pericarditis in SLE

Lupus science & medicine, 2017-10, Vol.4 (1), p.e000221-e000221

2017

Volltextzugriff (PDF)

Clinical and histopathological features of myositis in systemic lupus erythematosus

Lupus science & medicine, 2022-03, Vol.9 (1), p.e000635

2022

Volltextzugriff (PDF)

Does the use of corticosteroids and immunosuppressants increase the risk of COVID-19 infection among people with systemic lupus erythematosus?

Lupus science & medicine, 2023-10, Vol.10 (2), p.e000961

2023

Volltextzugriff (PDF)

High-risk coronary plaque in SLE: low-attenuation non-calcified coronary plaque and positive remodelling index

Lupus science & medicine, 2020-07, Vol.7 (1), p.e000409

2020

Volltextzugriff (PDF)

Loss of antiphospholipid antibody positivity post-thrombosis in SLE

Lupus science & medicine, 2020-10, Vol.7 (1), p.e000423

2020

Volltextzugriff (PDF)

The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial

Annals of internal medicine, 2005-06, Vol.142 (12 Pt 1), p.953

2005

Volltextzugriff (PDF)

Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways

Lupus science & medicine, 2020-10, Vol.7 (1), p.e000424

2020

Volltextzugriff (PDF)

H3K4 tri-methylation breadth at transcription start sites impacts the transcriptome of systemic lupus erythematosus

Clinical epigenetics, 2016-02, Vol.8 (14), p.14-14, Article 14

2016

Volltextzugriff (PDF)

Evaluation of different ways to identify persistent positivity of lupus anticoagulant in systemic lupus erythematosus

Lupus science & medicine, 2020-11, Vol.7 (1), p.e000406

2020

Volltextzugriff (PDF)

Novel evidence‐based systemic lupus erythematosus responder index

Arthritis and rheumatism, 2009-09, Vol.61 (9), p.1143-1151

2009

Volltextzugriff (PDF)

Renal response at 2 years post biopsy to predict long-term renal survival in lupus nephritis: a retrospective analysis of the Hopkins Lupus Cohort

Lupus science & medicine, 2022-08, Vol.9 (1), p.e000598

2022

Volltextzugriff (PDF)

Glycosphingolipid-associated β-1,4 galactosyltransferase is elevated in patients with systemic lupus erythematosus

Lupus science & medicine, 2020-07, Vol.7 (1), p.e000368

2020

Volltextzugriff (PDF)

Urinary HER2, TWEAK and VCAM-1 levels are associated with new-onset proteinuria in paediatric lupus nephritis

Lupus science & medicine, 2022-08, Vol.9 (1), p.e000719

2022

Volltextzugriff (PDF)

Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial

The Lancet (British edition), 2018-07, Vol.392 (10143), p.222-231

2018

Volltextzugriff (PDF)

Transcription Factor Activity Inference in Systemic Lupus Erythematosus

Life (Basel, Switzerland), 2021-04, Vol.11 (4), p.299

2021

Volltextzugriff (PDF)

Clinical, laboratory and health-related quality of life correlates of Systemic Lupus Erythematosus Responder Index response: a post hoc analysis of the phase 3 belimumab trials

Lupus science & medicine, 2014-06, Vol.1 (1), p.e000031-e000031

2014

Volltextzugriff (PDF)

Monocyte enhancers are highly altered in systemic lupus erythematosus

Epigenomics, 2015-09, Vol.7 (6), p.921-935

2015

Volltextzugriff (PDF)

Walter Bauer, Marian Wilkins Ropes, and the Massachusetts General Hospital

Rheumatic diseases clinics of North America, 2024-02, Vol.50 (1), p.79-92

2024

Volltextzugriff (PDF)

Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study

Annals of the rheumatic diseases, 2014-01, Vol.73 (1), p.183-190

2014

Volltextzugriff (PDF)

Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials

Annals of the rheumatic diseases, 2012-11, Vol.71 (11), p.1833-1838

2012

Volltextzugriff (PDF)

Therapy with granulocyte colony-stimulating factor in systemic lupus erythematosus may be associated with severe flares

Journal of rheumatology, 2006-09, Vol.33 (9), p.1878

2006

Volltextzugriff (PDF)

1 – 25 von 796

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(668)
Mit Volltextzugriff
(640)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(532)
Life Sciences & Biomedicine
(514)
Humans
(472)
Rheumatology
(375)
Female
(338)
Male
(257)
Adult
(255)
Systemic Lupus Erythematosus
(238)
Lupus
(224)
Middle Aged
(183)
Biological And Medical Sciences
(173)
Medical Sciences
(172)
Risk Factors
(112)
Lupus Erythematosus, Systemic - Drug Therapy
(96)
Lupus Erythematosus, Systemic - Complications
(95)
Severity Of Illness Index
(87)
Diseases Of The Osteoarticular System
(82)
Cohort Studies
(77)
Autoimmune Diseases
(76)
Patients
(74)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(7)

Menü

Weitere Dienste

Einstellungen

Differences between male and female systemic lupus erythematosus in a multiethnic population

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response

Associates and predictors of pleurisy or pericarditis in SLE

Clinical and histopathological features of myositis in systemic lupus erythematosus

Does the use of corticosteroids and immunosuppressants increase the risk of COVID-19 infection among people with systemic lupus erythematosus?

High-risk coronary plaque in SLE: low-attenuation non-calcified coronary plaque and positive remodelling index

Loss of antiphospholipid antibody positivity post-thrombosis in SLE

The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial

Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways

H3K4 tri-methylation breadth at transcription start sites impacts the transcriptome of systemic lupus erythematosus

Evaluation of different ways to identify persistent positivity of lupus anticoagulant in systemic lupus erythematosus

Novel evidence‐based systemic lupus erythematosus responder index

Renal response at 2 years post biopsy to predict long-term renal survival in lupus nephritis: a retrospective analysis of the Hopkins Lupus Cohort

Glycosphingolipid-associated β-1,4 galactosyltransferase is elevated in patients with systemic lupus erythematosus

Urinary HER2, TWEAK and VCAM-1 levels are associated with new-onset proteinuria in paediatric lupus nephritis

Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial

Transcription Factor Activity Inference in Systemic Lupus Erythematosus

Clinical, laboratory and health-related quality of life correlates of Systemic Lupus Erythematosus Responder Index response: a post hoc analysis of the phase 3 belimumab trials

Monocyte enhancers are highly altered in systemic lupus erythematosus

Walter Bauer, Marian Wilkins Ropes, and the Massachusetts General Hospital

Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study

Health information use by patients with systemic lupus erythematosus (SLE) pre and during the COVID-19 pandemic

Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials

Therapy with granulocyte colony-stimulating factor in systemic lupus erythematosus may be associated with severe flares

Suchergebnisse filtern